Report
Hyloris Pharma - Post-FY23 model revisions
*HYL's recent FY23 publication indicated 1/ a 44% increase YoY in its product revenue with significant further ramp-up expected in ‘24 with at least doubling of product revenue (mainly driven by commercial rollout of Maxigesic IV in the USA) and 2/ further increase in R&D expenses in ‘24.*As a result thereof and based on more in-depth analysis of the value proposition of each asset, we 1/ finetuned revenue & cost estimates for the coming years and 2/ aligned the clinical and commercial strategy for pipeline assets with the latest guidance. We also adjusted the number of additional assets in the
Underlying
Hyloris Pharmaceuticals
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.